Related Experiment Videos
Antithrombotic effects of tetramethylpyrazine in in vivo experiments
1Graduate Institute of Medical Sciences and Department of Pharmacology, Taipei Medical University, Taiwan. sheujr@tmc.edu.tw
Abstract:
In this study, tetramethylpyrazine (TMPZ) was effective in reducing the mortality of ADP-induced acute pulmonary thromboembolism in mice when administered intravenously at doses of 40 and 80 microg/g. In addition, intravenous injection of TMPZ (10 microg/g) significantly prolonged the bleeding time by approximately 1.5-fold compared with normal saline in severed mesenteric arteries of rats. Continuous infusion of TMPZ (1 microg/g per min) for 10 minutes also significantly increased the bleeding time approximately 1.6-fold, and the bleeding time returned to baseline within 60 minutes after cessation of TMPZ infusion. On the other hand, platelet thrombi formation was induced by irradiation of mesenteric venules with filtered light in mice pre-treated intravenously with fluorescein sodium (10 microg/kg). When it was intravenously injected, TMPZ (250 microg/g) significantly prolonged the latent period of the induction of platelet plug formation in mesenteric venules. TMPZ (250 microg/g) prolonged occlusion time approximately 1.4-fold (183 +/- 18 seconds) compared with that of normal saline (132 +/- 14 seconds). Furthermore, aspirin (300 microg/g) showed similar activity in the prolongation of occlusion time in this experiment. In conclusion, these results suggest that TMPZ has effective antithrombotic activity in vivo and may be a potential therapeutic agent for arterial thrombosis but must be assessed further for toxicity.
Insights
Tetramethylpyrazine (TMPZ) effectively reduced mortality in acute pulmonary thromboembolism and prolonged bleeding times in rat and mouse models. TMPZ demonstrated significant antithrombotic activity, suggesting its potential as a therapeutic agent.
Area of Science:
- Pharmacology
- Cardiovascular Research
- Hemostasis and Thrombosis
Background:
- Acute pulmonary thromboembolism poses a significant mortality risk.
- Arterial thrombosis is a major cause of cardiovascular events.
- Developing effective antithrombotic agents is crucial for clinical practice.
Purpose of the Study:
- To investigate the in vivo antithrombotic and hemostatic effects of tetramethylpyrazine (TMPZ).
- To evaluate TMPZ's efficacy in reducing mortality associated with acute pulmonary thromboembolism.
- To assess TMPZ's impact on platelet aggregation and thrombus formation.
Main Methods:
- Intravenous administration of TMPZ in mouse models of ADP-induced pulmonary thromboembolism.
- Assessment of bleeding time in rats with severed mesenteric arteries following TMPZ injection or infusion.
- Evaluation of TMPZ's effect on platelet plug formation in mice using laser-induced mesenteric venule thrombosis.
- Comparison of TMPZ's antithrombotic activity with aspirin.
Main Results:
- TMPZ significantly reduced mortality in acute pulmonary thromboembolism models.
- Intravenous TMPZ and continuous infusion prolonged bleeding times in rats.
- TMPZ significantly delayed platelet thrombi formation and prolonged occlusion time in mice.
- TMPZ exhibited antithrombotic activity comparable to aspirin.
Conclusions:
- Tetramethylpyrazine possesses significant in vivo antithrombotic activity.
- TMPZ demonstrates potential as a therapeutic agent for arterial thrombosis.
- Further toxicological assessment is warranted to evaluate TMPZ's safety profile.